New colorectal cancer drug Braftovi will receive reimb
By | translator Kim, Jung-Ju
24.01.11 14:18:59
가나다라
0
Ono Pharmaceutical held a press conference on 11th, commemorating reimbursement listing of colorectal cancer drug Braftovi in Korea
The combination therapy of Braftovi and cetuximab has shown efficacy and safety as a second-line treatment for colorectal cancer
Braftovi could serve as a 1st-line treatment for BRAF V600E colorectal cancer, which typically shows poor prognosis.
▲Ono Pharmaceutical Korea held a press conference celebrating reimbursement listing of Braftovi (ingredient: encorafenib), a targeted drug for the treatment of metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation.
All eyes are on Braftovi, a new targeted drug for metastatic colorectal cancer emerging after a 15-year gap, for its potential to address unmet demands for treatment options. Experts have assessed that, based on proven efficacy, Braftovi is likely to be highly utilized.
On the 11th, Ono Pharmaceutical Korea held a press conference celebrating the reimbursement listing of Braftovi (ingredient: encorafenib), a targeted drug for the treatment of metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation.
Braftovi is a targeted drug, emerged 15 years after Merck’s Erbitux (cetuximab), for the treatment of colorectal cancer. In Phase 3 BEACON CRC studies, Braftovi has demons
(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)